vs

Side-by-side financial comparison of IRIDEX CORP (IRIX) and PEDEVCO CORP (PED). Click either name above to swap in a different company.

PEDEVCO CORP is the larger business by last-quarter revenue ($23.1M vs $14.7M, roughly 1.6× IRIDEX CORP). On growth, PEDEVCO CORP posted the faster year-over-year revenue change (118.2% vs -69.7%). Over the past eight quarters, PEDEVCO CORP's revenue compounded faster (68.6% CAGR vs 11.9%).

IRIDEX Corporation is a global medical technology company that designs, manufactures and distributes advanced laser-based medical devices, primarily serving the ophthalmology and aesthetic medicine sectors. It supplies products to healthcare providers, clinics and medical facilities across North America, Europe, Asia Pacific and other regions, delivering minimally invasive solutions for eye disease treatment and cosmetic procedures.

PEDEVCO Corp is an independent energy company specializing in the acquisition, exploration, development, and production of oil and natural gas assets. It primarily holds and operates onshore resource properties across continental US basins, serving domestic wholesale, utility, and industrial energy customer segments.

IRIX vs PED — Head-to-Head

Bigger by revenue
PED
PED
1.6× larger
PED
$23.1M
$14.7M
IRIX
Growing faster (revenue YoY)
PED
PED
+188.0% gap
PED
118.2%
-69.7%
IRIX
Faster 2-yr revenue CAGR
PED
PED
Annualised
PED
68.6%
11.9%
IRIX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IRIX
IRIX
PED
PED
Revenue
$14.7M
$23.1M
Net Profit
$-8.5M
Gross Margin
37.2%
Operating Margin
-21.3%
Net Margin
-36.8%
Revenue YoY
-69.7%
118.2%
Net Profit YoY
-243.5%
EPS (diluted)
$-2.23

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IRIX
IRIX
PED
PED
Q4 25
$14.7M
$23.1M
Q3 25
$12.5M
$7.0M
Q2 25
$13.6M
$7.0M
Q1 25
$11.9M
$8.7M
Q4 24
$12.7M
$10.6M
Q3 24
$11.6M
$9.1M
Q2 24
$12.6M
$11.8M
Q1 24
$11.8M
$8.1M
Net Profit
IRIX
IRIX
PED
PED
Q4 25
$-8.5M
Q3 25
$-1.6M
$-325.0K
Q2 25
$-994.0K
$-1.7M
Q1 25
$-1.7M
$140.0K
Q4 24
$-834.0K
$5.9M
Q3 24
$-1.9M
$2.9M
Q2 24
$-2.7M
$2.7M
Q1 24
$-3.5M
$773.0K
Gross Margin
IRIX
IRIX
PED
PED
Q4 25
37.2%
Q3 25
32.1%
Q2 25
34.5%
Q1 25
42.5%
Q4 24
44.0%
Q3 24
37.3%
Q2 24
40.7%
Q1 24
37.9%
Operating Margin
IRIX
IRIX
PED
PED
Q4 25
-21.3%
Q3 25
-11.3%
-12.0%
Q2 25
-6.9%
-32.2%
Q1 25
-1.7%
1.7%
Q4 24
-3.9%
-12.9%
Q3 24
-16.1%
31.3%
Q2 24
-20.9%
22.3%
Q1 24
-28.0%
7.6%
Net Margin
IRIX
IRIX
PED
PED
Q4 25
-36.8%
Q3 25
-12.6%
-4.7%
Q2 25
-7.3%
-24.0%
Q1 25
-14.2%
1.6%
Q4 24
-6.6%
56.0%
Q3 24
-16.7%
32.2%
Q2 24
-21.2%
22.7%
Q1 24
-29.5%
9.5%
EPS (diluted)
IRIX
IRIX
PED
PED
Q4 25
$-2.23
Q3 25
$-0.09
$0.00
Q2 25
$-0.06
$-0.02
Q1 25
$-0.10
$0.00
Q4 24
$-0.05
$2.69
Q3 24
$-0.12
$0.03
Q2 24
$-0.16
$0.03
Q1 24
$-0.21
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IRIX
IRIX
PED
PED
Cash + ST InvestmentsLiquidity on hand
$6.0M
$3.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$207.4M
Total Assets
$29.2M
$375.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IRIX
IRIX
PED
PED
Q4 25
$6.0M
$3.2M
Q3 25
$5.6M
$10.9M
Q2 25
$6.8M
$8.5M
Q1 25
$7.2M
$10.4M
Q4 24
$2.4M
$4.0M
Q3 24
$3.9M
$4.6M
Q2 24
$4.1M
$6.1M
Q1 24
$5.4M
$13.3M
Total Debt
IRIX
IRIX
PED
PED
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$1.0M
Q3 24
$1.4M
Q2 24
Q1 24
Stockholders' Equity
IRIX
IRIX
PED
PED
Q4 25
$207.4M
Q3 25
$4.7M
$115.4M
Q2 25
$6.1M
$115.2M
Q1 25
$852.0K
$116.2M
Q4 24
$2.1M
$115.6M
Q3 24
$2.6M
$106.5M
Q2 24
$4.2M
$103.2M
Q1 24
$6.5M
$100.0M
Total Assets
IRIX
IRIX
PED
PED
Q4 25
$29.2M
$375.9M
Q3 25
$28.4M
$135.9M
Q2 25
$31.6M
$136.8M
Q1 25
$34.2M
$145.6M
Q4 24
$29.1M
$128.3M
Q3 24
$30.2M
$114.3M
Q2 24
$31.2M
$111.0M
Q1 24
$34.1M
$118.3M
Debt / Equity
IRIX
IRIX
PED
PED
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.48×
Q3 24
0.53×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IRIX
IRIX
PED
PED
Operating Cash FlowLast quarter
$-2.1M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IRIX
IRIX
PED
PED
Q4 25
$-2.1M
Q3 25
$-1.2M
$7.4M
Q2 25
$-397.0K
$-420.0K
Q1 25
$-1.1M
$5.9M
Q4 24
$-1.2M
$4.2M
Q3 24
$-3.1M
$8.3M
Q2 24
$-1.3M
$4.6M
Q1 24
$-1.6M
$-4.3M
Free Cash Flow
IRIX
IRIX
PED
PED
Q4 25
Q3 25
$-1.2M
Q2 25
$-410.0K
Q1 25
$-1.2M
Q4 24
$-1.2M
Q3 24
$-3.1M
Q2 24
Q1 24
$-1.7M
FCF Margin
IRIX
IRIX
PED
PED
Q4 25
Q3 25
-9.4%
Q2 25
-3.0%
Q1 25
-9.8%
Q4 24
-9.8%
Q3 24
-26.5%
Q2 24
Q1 24
-14.0%
Capex Intensity
IRIX
IRIX
PED
PED
Q4 25
Q3 25
0.1%
Q2 25
0.1%
Q1 25
0.1%
Q4 24
0.1%
Q3 24
0.0%
Q2 24
0.0%
Q1 24
0.0%
Cash Conversion
IRIX
IRIX
PED
PED
Q4 25
Q3 25
Q2 25
Q1 25
42.34×
Q4 24
0.71×
Q3 24
2.83×
Q2 24
1.71×
Q1 24
-5.56×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons